Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 09  •  04:00PM ET
27.82
Dollar change
+0.30
Percentage change
1.09
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y18.59% Total Holdings65 Perf Week6.10%
SponsorBlackrock (iShares) ETF Type Tagsequity Return% 3Y3.28% AUM139.14M Perf Month5.74%
Fund Family Bond Type Tagshealthcare Return% 5Y-8.95% NAV/sh Perf Quarter13.27%
IndexNYSE FactSet Global Genomics and Immuno... Average Maturity Tagsgenomics Return% 10Y 52W High28.10 -1.00% Perf Half Y31.29%
Index Weighting Commodity Type Tagspharmaceutical Return% SI 52W Low17.26 61.18% Perf YTD6.22%
Active/Passive Quant Type Tagsinnovation Flows% 1M0.00% Volatility2.21% 1.48% Perf Year17.73%
Dividend TTM0.31 (1.11%) ESG Type Tags- Flows% 3M0.02% ATR (14)0.49 Perf 3Y7.25%
Dividend Ex-DateDec 16, 2025 Dividend Type Sector/Theme Flows% YTD0.00% RSI (14)63.74 Perf 5Y-39.80%
Dividend Gr. 3/5Y31.32% 20.75% Structure Type Region Flows% 1Y Beta1.03 Perf 10Y-
Expense0.47% Growth/Value SMA204.47% Flows% 3Y Rel Volume0.50 Prev Close27.52
Inverse/Leveraged Market Cap SMA505.78% Flows% 5Y Avg Volume32.65K Price27.82
IPOJun 13, 2019 Option/ShortYes / Yes SMA20022.12% Trades Volume16,655 Change1.09%
Jan-09-26 10:00AM
May-02-25 03:25AM
Apr-30-25 04:35AM
04:33AM
Apr-23-25 05:45AM
11:28AM Loading…
Apr-20-25 11:28AM
Apr-18-25 01:40PM
Apr-04-25 08:30AM
Apr-02-25 07:00AM
Apr-01-25 05:40AM
Mar-28-25 06:05AM
Mar-20-25 04:32PM
Sep-09-22 01:45PM
Mar-30-22 01:30PM
Feb-25-22 09:59PM
10:15AM Loading…
Dec-06-21 10:15AM
Oct-21-21 10:15AM
May-18-20 03:42PM
10:51AM
Dec-23-19 12:00PM
Dec-18-19 01:41PM
Nov-25-19 06:55PM
Nov-21-19 12:56PM
Nov-04-19 01:00PM
Oct-23-19 10:10AM
Sep-06-19 03:07PM
Sep-04-19 03:18PM
iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.